StockDuty ← Dashboard Aug 07, 2026 08:51 AM ET
SignalFDA/Bio

Cognition Therapeutics Q2 Net Loss Narrows; Plans Phase 3 DLB Study Of Zervimesine In Mid 2027

Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027.

Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027.
Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027. — impact context not separately stored; see What changed.
Sources